Asset Details
Do you wish to reserve the book?
Endothelial dysfunction: a strategic target in the treatment of hypertension?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Endothelial dysfunction: a strategic target in the treatment of hypertension?
Do you wish to request the book?
Endothelial dysfunction: a strategic target in the treatment of hypertension?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Endothelial dysfunction: a strategic target in the treatment of hypertension?
2010
Overview
Endothelial dysfunction is a common feature of hypertension, and it results from the imbalanced release of endothelium-derived relaxing factors (EDRFs; in particular, nitric oxide) and endothelium-derived contracting factors (EDCFs; angiotensin II, endothelins, uridine adenosine tetraphosphate, and cyclooxygenase-derived EDCFs). Thus, drugs that increase EDRFs (using direct nitric oxide releasing compounds, tetrahydrobiopterin, or
l
-arginine supplementation) or decrease EDCF release or actions (using cyclooxygenase inhibitor or thromboxane A2/prostanoid receptor antagonists) would prevent the dysfunction. Many conventional antihypertensive drugs, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and third-generation β-blockers, possess the ability to reverse endothelial dysfunction. Their use is attractive, as they can address arterial blood pressure and vascular tone simultaneously. The severity of endothelial dysfunction correlates with the development of coronary artery disease and predicts future cardiovascular events. Thus, endothelial dysfunction needs to be considered as a strategic target in the treatment of hypertension.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
/ Animals
/ Antihypertensive Agents - therapeutic use
/ Biomedical and Life Sciences
/ Calcium - administration & dosage
/ Dinucleoside Phosphates - pharmacology
/ Endothelium, Vascular - physiopathology
/ Endothelium-Dependent Relaxing Factors
/ Humans
/ Hypertension - physiopathology
/ Prostaglandin-Endoperoxide Synthases - metabolism
/ Reactive Oxygen Species - metabolism
/ Receptor, Endothelin A - physiology
/ Receptor, Endothelin B - physiology
